Endogenous Fungal Endophthalmitis: A Single-Center Retrospective Study and Review of the Literature

Eleanor Burton,Vishal Reddy,Arthi G Venkat,Arthi G. Venkat

DOI: https://doi.org/10.1016/j.ajo.2024.01.018

IF: 5.488

2024-01-28

American Journal of Ophthalmology

Abstract:Purpose To evaluate factors that inform systemic antifungal choices in patients with endogenous fungal endophthalmitis (EFE). Design Single institution retrospective case series. Methods Charts of EFE patients from 2010 to 2023 were reviewed. Patients treated systemically for EFE with a minimum of 14 days of follow-up were included. Outcome measures included time to improvement in vitritis or chorioretinitis, systemic therapy modification, and need for surgical intervention. Results Twenty eyes of 16 patients were included. Candida species were most common (43.8%), followed by culture negative EFE (37.5%) and Aspergillus species (18.8%). Ninety percent of eyes had vitritis and/or macula-involving chorioretinitis. Most Candida infections (60%) or culture negative EFE (75%) were treated initially with oral antifungals. Patients with a history of immune compromise, positive fungal culture or positive Fungitell assay were more likely to be treated with early intravenous (IV) antifungal therapy. Two cases required systemic antifungal therapy modification due to worsening chorioretinitis: in one case due to voriconazole-resistant Aspergillosis that demonstrated chorioretinal lesion growth despite intravitreal amphotericin B injections and systemic voriconazole, and in a second case due to worsening chorioretinitis from C. dubliniensis infection that regressed upon switch from oral to IV fluconazole. Conclusion Initial systemic treatment decisions in patients with EFE were driven by systemic culture positivity, systemic symptoms, or comorbidities. Intravitreal antifungal therapy may be insufficient to arrest progression of chorioretinal lesions in some cases. Larger studies are needed to determine whether visible end-organ damage in the form of chorioretinitis may be useful for guiding systemic therapy changes.

ophthalmology